Literature DB >> 11789491

Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage.

A Becker1, R Fischer, W A Scherbaum, M Schneider.   

Abstract

The aim of the present study was to assess the effects of disease severity and demonstrable organ damage as risk factors for the development of osteoporosis in systemic lupus erythematosus (SLE). Sixty-four SLE patients were included. Mean disease duration was 7.7 +/- 5.7 y. Thirty-two patients had persistent organ damage, defined as SLICC-ACR damage score > or = 1. Disease activity measured by SLAM-2 ranged from 3 to 27. Bone mineral density (BMD) measurements were performed with dual X-ray absorptiometry. In addition, biochemical markers of bone metabolism were studied. BMD was inversely correlated with disease duration, damage score and cumulative glucocorticoid intake, but no correlation was found for current glucocortioid use or with markers of bone metabolism. In a multivariate analysis, body weight, disease duration and damage index fitted best for the prediction of BMD at both lumbar spine and femoral neck. Seven out of 64 patients had osteoporosis according to WHO criteria. In conclusion, severe osteoporosis is uncommon in lupus patients. Disease activity and severity were no major risk factors for loss of BMD in this study, but persistent non-bone-related organ damage was significantly linked to the presence of osteoporosis measured as decreased BMD. Our data suggest that, in addition to patients receiving glucocorticoids, patients with an SLICC-ACR > or = 1 or a disease duration > or = 7 y might benefit from regular monitoring of BMD as secondary prevention of damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11789491     DOI: 10.1177/096120330101001108

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  19 in total

Review 1.  Bone health and systemic lupus erythematosus.

Authors:  Chin Lee; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

Review 2.  Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  X Wang; S Yan; C Liu; Y Xu; L Wan; Y Wang; W Gao; S Meng; Y Liu; R Liu; D Xu
Journal:  Osteoporos Int       Date:  2016-01-11       Impact factor: 4.507

3.  Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.

Authors:  L P C Seguro; C B Casella; V F Caparbo; R M Oliveira; A Bonfa; E Bonfa; R M R Pereira
Journal:  Osteoporos Int       Date:  2014-08-22       Impact factor: 4.507

4.  Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis.

Authors:  Kui Zhang; Yan Zheng; Junfeng Jia; Jin Ding; Zhenbiao Wu
Journal:  Clin Rheumatol       Date:  2017-09-25       Impact factor: 2.980

5.  Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.

Authors:  J Jacobs; L-A Korswagen; A M Schilder; L H van Tuyl; B A C Dijkmans; W F Lems; A E Voskuyl; I E M Bultink
Journal:  Osteoporos Int       Date:  2012-10-03       Impact factor: 4.507

Review 6.  Bone health in systemic lupus erythematosus.

Authors:  Pantelis Panopalis; Jinoos Yazdany
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

7.  Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Hilda Sandoval-Cruz; Ricardo O Escárcega; Mario Jiménez-Hernández; Ivet Etchegaray-Morales; Elena Soto-Vega; Margarita Muñoz-Guarneros; Aurelio López-Colombo; Margarita Delezé-Hinojosa; Ricard Cervera
Journal:  Clin Rheumatol       Date:  2008-08-01       Impact factor: 2.980

Review 8.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

9.  The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Authors:  H P Bhattoa; P Bettembuk; A Balogh; G Szegedi; E Kiss
Journal:  Osteoporos Int       Date:  2003-12-16       Impact factor: 4.507

Review 10.  [Modern therapy for systemic lupus erythematosus].

Authors:  R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.